Active hepatitis B or hepatitis C infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Known history of hepatitis C infection or suspected currently active hepatitis C infection; known or suspected history of hepatitis B infection will be excluded when any of the following conditions are met:\r\n* Received hematopoietic stem cell transplantation (either allogenic or autologous), or\r\n* Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or\r\n* Active hepatitis B as deemed by serology or viral load
Active hepatitis B infection
Active hepatitis C infection
Active hepatitis A, B, or C infection.
Has a known history of hepatitis B and/or hepatitis C infection
Active or chronic hepatitis B or C infection\r\n* Previously infected with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion
Active hepatitis B and/or hepatitis C infection
Active Hepatitis B or C infection
Active hepatitis A, B, or C infection
A history of active hepatitis B and/or hepatitis C infection
Participant has known infection with hepatitis B or hepatitis C.
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients with known active hepatitis B and/or active hepatitis C infection
Patients with known active Hepatitis B or Hepatitis C infection
Active hepatitis A, hepatitis B, or hepatitis C infection
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Active hepatitis B or C infection
Active hepatitis B or C infection
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Known hepatitis B or hepatitis C infection
Subjects with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Active hepatitis B or C infection
COHORT 3: ENDOMETRIAL CANCER: Patients who have known active hepatitis B, or hepatitis C infection
Active Hepatitis C infection. Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ? 12 weeks.
Known active hepatitis infection
Active hepatitis A, hepatitis B, or hepatitis C infection
Active hepatitis B or hepatitis C infection
Has an active bacterial, fungal, and/or known viral infection; patients with known human immunodeficiency virus (HIV) infection are excluded given the potential for interactions between antiretroviral agents and abemaciclib, and the potential for increased risk of life threatening infection with therapy that is myelosuppressive; patients with known hepatitis B or hepatitis C infection are excluded only if there is evidence of active infection (detectable hepatitis B surface antigen, detectable hepatitis C ribonucleic acid [RNA])
Active hepatitis B or C infection
Active hepatitis A, B or C infection
Active infection with hepatitis B; active or chronic infection with hepatitis C
Prior or ongoing liver disease including known cirrhosis, active hepatitis B or C infection; not to exclude patients with a distant history of resolved hepatitis A infection
Known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.
Active hepatitis B or C infection
Active hepatitis B or C infection
Known history of hepatitis C or known active hepatitis B infection
No active infection with Hepatitis B.
No active infection with Hepatitis C.
Known hepatitis B or C infection
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Active, uncontrolled infection including known hepatitis B or C
Known or suspected active hepatitis B or C infection
Known active hepatitis B or C infection, or HIV infection.
Active hepatitis B or hepatitis C infection
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Active hepatitis B or hepatitis C infection
Participants with active hepatitis A, B or C infection.
Known active hepatitis B and/or hepatitis C infection
Patients tested positive for hepatitis B or with a known, active hepatitis C infection
Known active Hepatitis B or C infection
Negative for hepatitis A, B, or C infection
Patients with active hepatitis B and/or hepatitis C infection
Active hepatitis B or hepatitis C infection
Known active hepatitis B or C infection
Any history of hepatitis B infection
Relapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Newly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation
Patients with active hepatitis B and/or hepatitis C infection
Active hepatitis B or C infection
Known positivity for hepatitis B infection
Known active hepatitis C infection
Patients with a history of hepatitis B with persistent infection.
Active, uncontrolled infection (e.g. Hepatitis A, B, or C)
Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C.
Subject has known active hepatitis B or hepatitis C infection.
Active hepatitis B or hepatitis C infection at the time of screening
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Known HIV infection or active infection with hepatitis B or C. Patients with unknown status at the time of enrollment must be tested during screening.
Serologic status reflecting active hepatitis B or C infection.
Active viral hepatitis infection. Subjects with history of hepatitis infection that is not active are eligible.
Active hepatitis B or hepatitis C infection
Active hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease. These patients should be optimized by GI consultation for hepatitis B and infectious disease consult for hepatitis C.
Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation.
Has known active hepatitis B or hepatitis C infection
Known active hepatitis B or active hepatitis C infection; participants who have prior hepatitis C infection but who have received an antiviral treatment and show no detectable viral ribonucleic acid (RNA) for 6 months after completion of treatment are eligible
Known active hepatitis B or C infection or HIV infection.
Active hepatitis B or C infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Known, active hepatitis A, B, or C infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Co-infection with hepatitis B
Known active hepatitis A, B, or C infection that requires treatment
Active infection with hepatitis B; active or chronic infection with hepatitis C
Active hepatitis B or C infection
Patients with active hepatitis B or active hepatitis C infection
Active hepatitis B or C infection
Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
Active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive )
Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection
Active hepatitis B or C infection based on screening blood testing
Hepatitis D infection in subjects with hepatitis B
Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection.
Has known active Hepatitis B or Hepatitis C infection.
Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection
No active infection with hepatitis B
Known active hepatitis B or hepatitis C infection.
Active infection or past hepatitis B or C infection
Hepatitis B or C infection
Known history of active hepatitis B or hepatitis C infection
Active hepatitis B or hepatitis C infection
Hepatitis B or C infection
known or suspected past hepatitis B infection,
Active hepatitis B infection, active hepatitis C infection or known HIV carrier.
Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B and C virus
Active hepatitis B or C infection
History of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this study
Active, uncontrolled infection, including hepatitis B, hepatitis C
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation
Evidence of active hepatitis B (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody) or active hepatitis C infection; evidence of active human immunodeficiency virus (HIV) infection
Known active hepatitis B or C infection
No active hepatitis B or C infection
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Active hepatitis B infection, active hepatitis C infection
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Active hepatitis B or C infection.
Active hepatitis B or C infection
Participant has known active infection with hepatitis B or hepatitis C virus; hepatitis B and C serology testing is not required, unless active infection is suspected
Known active hepatitis B or C infection
Active hepatitis A, B, or C infection
Active hepatitis B or hepatitis C infection
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Active hepatitis B or C infection
Subjects with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Active hepatitis B or C infection
Active hepatitis B or C infection
Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection
Patients known to be positive for hepatitis B or to have active hepatitis C infection;
Evidence of active or prior hepatitis infection.
Known infection with HIV and active infection with hepatitis B or C.
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
7. Subjects with known infection with hepatitis A, B or C (testing not required).
Known infection with HIV or active infection with hepatitis B or hepatitis C
Active hepatitis B or C infection
History of HIV infection or acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines
Known HIV infection and/or active Hepatitis B or C infection
Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation
Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection
Active hepatitis B infection active hepatitis C infection and/or known HIV carrier.
Uncontrolled, active infection; patients who are known to have HIV infection/ seropositivity, Hepatitis A, B, or C, or CMV reactivation
Evidence of hepatitis B infection
DONOR: Evidence of hepatitis B infection
Known active hepatitis B or C infection
Active hepatitis B or C infection
Active hepatitis B or C infection
Patients with documented active hepatitis B or C infection
Active hepatitis B or active hepatitis C infection
Hepatitis B or hepatitis C active infection
